🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

342 results for “Novartis Pharmaceuticals” Clear

  1. Secukinumab (75 mg)

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial

  2. Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  3. TENOFOVIR DISOPROXIL , ENTECAVIR , VAY736, -, Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR ALAFENAMIDE

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  4. TERIFLUNOMIDE, INTERFERON BETA-1A, DIROXIMEL FUMARATE, INTERFERON BETA-1A, INTERFERON BETA-1A, GLATIRAMER ACETATE, Betaferon 250 microgram/ml, powder and solvent for solution for injection, OFATUMUMAB, GLATIRAMER ACETATE, DIMETHYL FUMARATE, PEGINTERFERON BETA-1A, DIMETHYL FUMARATE

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  5. TQJ230

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  6. TQJ230, INCLISIRAN, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  7. TQJ230, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Pharmaceuticals

    Apheresis

    phase 3 small molecule active

    1 trial

  8. Tasigna 200 mg hard capsules, DASATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, IMATINIB, DASATINIB, NILOTINIB, BOSUTINIB, BOSUTINIB, Tasigna 150 mg hard capsules, DASATINIB, Tasigna 150 mg hard capsules, Tasigna 150 mg hard capsules, IMATINIB, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, ASCIMINIB HYDROCHLORIDE, Tasigna 200 mg hard capsules

    Novartis Pharmaceuticals

    chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  9. Telbivudine

    Novartis Pharmaceuticals

    Hepatitis

    phase 3 small molecule completed

    1 trial

  10. VAY736

    Novartis Pharmaceuticals

    Sjogren Syndrome

    phase 3 mab active

    1 trial

  11. VAY736, -, Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  12. VAY736, ENTECAVIR , Placebo to VAY736, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  13. Vildagliptin

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  14. Vildagliptin

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  15. YTB323, TISAGENLECLEUCEL, PHE885

    Novartis Pharmaceuticals

    All patients who have been treated with Novartis or Penn CAR T-cell therapy for any indication

    phase 3 small molecule active

    1 trial

  16. Zoledronic acid

    Novartis Pharmaceuticals

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  17. Zoledronic acid

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  18. Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  19. canakinumab

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 3 small molecule terminated

    2 trials

  20. ianalumab

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  21. ianalumab s.c. q4w

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule active

    1 trial

  22. secukinumab

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule terminated

    1 trial

  23. telbivudine or lamivudine

    Novartis Pharmaceuticals

    Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial

  24. zigakibart

    Novartis Pharmaceuticals

    Kidney Diseases

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources